Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
Published: 01 September 2020
-
Views:
1688
-
Likes:
7
-
Views:
1688
-
Likes:
7
-
Up Next
-
13m 38sPart 5 Q&As
-
2m 4sPart 1 Welcome Kurt Huber
-
15m 14sPart 2 Pre-treatment in NSTE-ACS – Dead or Alive? Davide Capodanno
-
18m 1sPart 3 Choice of Antithrombotic Agent in ACS: REACT-ing to Recent Trials Stefan James
Overview
In this series of videos Kurt Huber, Davide Capodanno, Stefan James and Roxana Mehran discuss Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
Learning Objectives
- Review the clinical landscape for antiplatelet therapy in patients with ACS.
- Discuss recent data on DAPT for patients with ACS
- Provide expert insight on application in routine clinical practice
More from this programme
Part 2
Pre-treatment in NSTE-ACS – Dead or Alive?
Part 3
Choice of Antithrombotic Agent in ACS: REACT-ing to Recent Trials
Part 4
When to leave Aspirin behind?
| 1 session | |
| When to leave Aspirin behind? | Watch now |
Faculty Biographies
Roxana Mehran
Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.
Roxana serves on editorial board of multiple peer reviewed journals, including …